Aligos Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Aligos Therapeutics, Inc. (ALGS) reported Increase (Decrease) in Accounts Payable of $2.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Aligos Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$1.21M.
- Aligos Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $3.66M, a 111.39% increase year-over-year.
- Aligos Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$669.00K.
- Aligos Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $752.00K.
- Aligos Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was $1.41M, a 2512.96% increase from fiscal 2024.
- Aligos Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was $54.00K.
- Aligos Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$2.22M, a 228.86% decline from fiscal 2022.
- Aligos Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was $1.72M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.45M 10-Q · filed 2026-08-06 | $1.78M derived: sum of 3 quarters · filed 2026-08-06 | $2.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.66M 10-Q · filed 2026-05-07 | $2.99M derived: sum of 2 quarters · filed 2026-05-07 | $3.74M derived: sum of 3 quarters · filed 2026-05-07 | $3.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$669.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $83.00K derived: sum of 2 quarters · filed 2026-03-05 | -$319.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.41M 10-K · filed 2026-03-05 |
| 2025-09-30 | $752.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $350.00K derived: sum of 2 quarters · filed 2026-08-06 | $2.08M 10-Q · filed 2025-11-06 | $1.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$402.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.33M 10-Q · filed 2026-08-06 | $1.16M derived: sum of 3 quarters · filed 2026-08-06 | -$2.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.73M 10-Q · filed 2026-05-07 | $1.56M derived: sum of 2 quarters · filed 2026-05-07 | -$2.52M derived: sum of 3 quarters · filed 2026-05-07 | $1.46M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$169.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$4.25M derived: sum of 2 quarters · filed 2026-03-05 | -$271.00K derived: sum of 3 quarters · filed 2026-03-05 | $54.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | -$4.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$102.00K derived: sum of 2 quarters · filed 2025-11-06 | $223.00K 10-Q · filed 2025-11-06 | -$200.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $4.30M 10-Q · filed 2025-08-06 | $3.88M derived: sum of 3 quarters · filed 2025-08-06 | $3.58M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $325.00K 10-Q · filed 2025-05-06 | -$98.00K derived: sum of 2 quarters · filed 2025-05-06 | -$398.00K derived: sum of 3 quarters · filed 2025-05-06 | $21.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | -$423.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$723.00K derived: sum of 2 quarters · filed 2025-03-10 | -$304.00K derived: sum of 3 quarters · filed 2025-03-10 | -$2.22M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $119.00K derived: sum of 2 quarters · filed 2024-11-06 | -$1.80M 10-Q · filed 2024-11-06 | $10.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $419.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$1.50M 10-Q · filed 2024-08-06 | $310.00K derived: sum of 3 quarters · filed 2024-08-06 | $479.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$1.92M 10-Q · filed 2024-05-07 | -$109.00K derived: sum of 2 quarters · filed 2024-05-07 | $60.00K derived: sum of 3 quarters · filed 2024-05-07 | -$933.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.98M derived: sum of 2 quarters · filed 2024-03-12 | $982.00K derived: sum of 3 quarters · filed 2024-03-12 | $1.72M 10-K · filed 2024-03-12 |
| 2022-09-30 | $169.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$824.00K derived: sum of 2 quarters · filed 2023-11-02 | -$84.00K 10-Q · filed 2023-11-02 | $315.00K derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$993.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$253.00K 10-Q · filed 2023-08-03 | $146.00K derived: sum of 3 quarters · filed 2023-08-03 | $1.27M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $740.00K 10-Q · filed 2023-05-04 | $1.14M derived: sum of 2 quarters · filed 2023-05-04 | $2.26M derived: sum of 3 quarters · filed 2023-05-04 | $929.00K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $399.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.52M derived: sum of 2 quarters · filed 2023-03-09 | $189.00K derived: sum of 3 quarters · filed 2023-03-09 | -$313.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$210.00K derived: sum of 2 quarters · filed 2022-11-02 | -$712.00K 10-Q · filed 2022-11-02 | -$4.52M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | -$1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$1.83M 10-Q · filed 2022-08-04 | -$5.64M derived: sum of 3 quarters · filed 2022-08-04 | -$1.88M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$502.00K 10-Q · filed 2022-05-04 | -$4.31M derived: sum of 2 quarters · filed 2022-05-04 | -$543.00K derived: sum of 3 quarters · filed 2022-05-04 | -$328.00K derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$3.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$41.00K derived: sum of 2 quarters · filed 2022-03-10 | $174.00K derived: sum of 3 quarters · filed 2022-03-10 | -$130.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $3.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.98M derived: sum of 2 quarters · filed 2021-11-04 | $3.68M 10-Q · filed 2021-11-04 | $4.31M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $215.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$89.00K 10-Q · filed 2021-08-05 | $544.00K derived: sum of 3 quarters · filed 2021-08-05 | |
| 2020-03-31 | -$304.00K 10-Q · filed 2021-05-10 | $329.00K derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $633.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $385.00K 10-K · filed 2021-03-23 | ||
| 2019-09-30 | -$248.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |